Maintenance Chemotherapy in Non-Small Cell Lung Cancer

被引：25

作者：

Eaton, Keith D. ^{[1
]}

Martins, Renato G. ^{[1
]}

机构：

[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98109 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2010年 / 8卷 / 07期

关键词：

NSCLC; non-small cell lung cancer; maintenance chemotherapy; review; PHASE-III TRIAL; CARBOPLATIN; DOCETAXEL; ERLOTINIB; CETUXIMAB;

D O I：

10.6004/jnccn.2010.0058

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Recent trials have shown a benefit with maintenance therapy after 4 to 6 cycles of chemotherapy. These trials have shown improvement in progression-free survival using agents approved as second-line therapy in non-small cell lung cancer. Trials using erlotinib and pemetrexed showed improvement in overall survival. Consideration of trial design is critical for the interpretation of these results. Data on quality of life and cost have not been presented, but will ultimately be important in evaluating the usefulness of these approaches. (JNCCN 2010;8:815-821)

引用

页码：815 / 821

页数：7

共 22 条

[1]

[Anonymous], 2010, TARC

[2]

[Anonymous], J THORAC ONCOL

[3]

Cappuzzo F, 2009, J CLIN ONCOL, V27

[4]

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[5]

Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis [J].

Delbaldo, C ;

Michiels, S ;

Syz, N ;

Soria, JC ;

Le Chevalier, T ;

Pignon, JP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :470-484

[6]

ETTINGER DS, 2010, NCCN CLIN PRACTICE G

[7]

Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer [J].

Fidias, Panos M. ;

Dakhil, Shaker R. ;

Lyss, Alan P. ;

Loesch, David M. ;

Waterhouse, David M. ;

Bromund, Jane L. ;

Chen, Ruqin ;

Hristova-Kazmierski, Maria ;

Treat, Joseph ;

Obasaju, Coleman K. ;

Marciniak, Martin ;

Gill, John ;

Schiller, Joan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :591-598

[8]

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9]

TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[10]

HERBST RS, 2005, J CLIN ONCOL, V23, P1

← 1 2 3 →